Jazz Receives No Vote 2-20

Well it appears the bears on the panel had their way as I had feared. In a previous post (post here) I noted concerns that Dr. Wolfe would attempt to hijack the panel hearing for Jazz’s JZP-6 and it appears him and Dr. Kosten were able to do so. I said from the get go that I believed that Dr. Wolfe has now become a political » Read more: Jazz Receives No Vote 2-20: Share Price Target

Alright, So I have gotten quite a few questions about what kind of price target I think Jazz Pharmaceuticals could hit if given different outcomes. So let me run through them. Also don’t forget my deal of the day, today back by popular demand I have the TradeKing deal. » Read more: Jazz Pharmaceuticals Share Price Targets for Different Outcomes

Jazz Pharmaceuticals (JAZZ): Briefing Document Analysis

Alright pharma investors time for a rundown on the Briefing Documents, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, so if you are looking for some type of product let me know and I’ll see what I can dig up. » Read more: Jazz Pharmaceuticals (JAZZ): Briefing Document Analysis

Get 100 Commission-Free Trades at OptionsHouse.com!

Jazz Pharmaceuticals (JAZZ): JZP-6 Overview for Tomorrow’s Briefing Document Release

Alright Jazz investors, I’m going to give a rundown of JZP-6 in preparation of the FDA’s release of the Briefing Documents tomorrow. I’ll list the supporting information and some of the concerns that I have ahead of the FDA review. I’ll go through the Pros first and the Risks second. » Read more: Jazz Pharmaceuticals (JAZZ): JZP-6 Overview for Tomorrow’s Briefing Document Release

Get 100 Commission-Free Trades at OptionsHouse.com!

So anytime there is an Advisory hearing I like to post a timeline of events that will occur before the panel meeting. On August 20, 2010, the FDA will meet with Jazz Pharmaceuticals to discuss their fibromyalgia drug JZP-6, » Read more: Jazz Pharmaceuticals (JAZZ): Briefing Document Reminder

Alright pharma investors time for a rundown on Arena, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, so if you are looking for some type of product let me know and I’ll see what I can dig up. » Read more: Arena’s (ARNA) Lorcaserin MUST READ Update

Alright pharma investors time for a rundown on Jazz, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, so if you are looking for some type of product let me know and I’ll see what I can dig up. Today I have partnered with Trade King to bring my fellow investors a good deal. Simply follow the link below and you will get a FREE $50 when you open an account with TradeKING, that’s right $50! Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!

Get $50 when you open a TradeKing account today.

Jazz Pharmaceuticals (JAZZ): JZP-6 Inside R.E.M.S.

So it is no secret that one of the larger hurdles that Jazz Pharmaceuticals must jump over for getting JZP-6 approved is a comprehensive risk Evaluation and Mitigation Strategy. JZP-6 is basically sodium oxybate, sodium oxybate, which is also known as GHB carries an increased risk of misuse among patients. » Read more: Jazz Pharmaceuticals (JAZZ): JZP-6 Inside R.E.M.S.

Jazz Pharmaceuticals (JAZZ):

A lot of readers are wondering what kind of prices Jazz Pharmaceuticals might try to charge for their drug JZP-6 if it gets approved. To do this, it might be important to look at the pricing points on the lead competitor drug in the fibromyalgia treatment field, Lyrica. » Read more: Jazz Pharmaceuticals (JAZZ): JZP-6 Part III Market Share

Jazz Pharmaceuticals (JAZZ) JZP-6 Fibromyalgia Market Quick update

So normally I don’t follow the larger pharma companies on my blog, but I do keep a keen eye out on all stocks. This morning Pfizer reported strong results, but why would this be important for Jazz Pharmaceuticals?

Pfizer makes a drug that is a direct competitor drug to JZP-6 called Lyrica. Lyrica, as I noted in a Post yesterday (here) has become one of Pfizer’s leading blockbusters. In June 2007, the drug received FDA approval to be sold to fibromyalgia patients. » Read more: Jazz Pharmaceuticals (JAZZ) JZP-6 Fibromyalgia Market Quick update

Jazz Pharmaceuticals (JAZZ) JZP-6 Analysis Part II

Before I go any further I would like to point out that this will be a 4-5 part analysis. This part will give a comprehensive overview of Fibromyalgia and current Fibromyalgia drugs out there since the field is dominated by stiff competition from two blockbuster drugs made by Pfizer and Eli Lilly. In the next part I’ll go over some of the concerns about JZP-6 and issues that may arise at the panel hearing. » Read more: Jazz Pharmaceuticals (JAZZ) JZP-6 Analysis Part II